In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

KYOTO Heart Study: Effects of Valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events

Hot Line III

Prevention



Presenter | see Discussant report

Hiroaki Matsubara (Japan)

Presentation webcast

Presentation slides

List of Authors:
H.Matsubara, T.Sawada, T.Takahashi, H.Yamada, B.Dahröf

Abstract:

Aims
The objective was to assess the add-on effect of valsartan on top of the conventional treatment for high risk hypertension in terms of the morbidity and mortality.

Methods and results
The KYOTO HEART study was of a multicentre, Prospective Randomised Open Blinded Endpoint (PROBE) design, and the primary endpoint was a composite of fatal and non-fatal cardiovascular events (clintrials.gov NCT00149227). 3031 Japanese patients (43% female, mean 66 years) with uncontrolled hypertension were randomized to either valsartan add-on or non-ARB treatment. Median follow-up period was 3.27 years. In both groups, blood pressure at baseline was 157/88 mmHg, and 133/76 mmHg at the end of study. Compared with non-ARB arm, valsartan add-on arm had fewer primary endpoints (83 vs 155; HR 0.55, 95% CI 0.42-0.72, p=0.00001).

Conclusion
Valsartan add-on treatment to improve blood pressure control prevented more cardiovascular events than conventional non-ARB treatment in high-risk hypertensive patients in Japan. These benefits cannot be entirely explained by a difference in blood pressure control.


Discussant | see Presenter abstract

 Frank Ruschitzka, FESC (Switzerland)

 







 

Presentation webcast

Report:

The objective was to assess the add-on effect of valsartan on top of the conventional treatment for high risk hypertension in terms of the morbidity and mortality.The KYOTO HEART study was of a multicentre, Prospective Randomised Open Blinded Endpoint (PROBE) design, and the primary endpoint was a composite of fatal and non-fatal cardiovascular events (clintrials.gov NCT00149227). 3031 Japanese patients (43% female, mean 66 years) with uncontrolled hypertension were randomized to either valsartan add-on or non-ARB treatment. Median follow-up period was 3.27 years. In both groups, blood pressure at baseline was 157/88 mmHg, and 133/76 mmHg at the end of study. Compared with non-ARB arm, valsartan add-on arm had fewer primary endpoints (83 vs 155; HR 0.55, 95% CI 0.42-0.72, p=0.00001).Valsartan add-on treatment to improve blood pressure control prevented more cardiovascular events than conventional non-ARB treatment in high-risk hypertensive patients in Japan. These benefits cannot be entirely explained by a difference in blood pressure control.

References


3582-3583

SessionTitle:

Effects of Valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (KYOTO Heart Study)

Notes to editor


This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.